NeuroVoices: Katrina Bawden, MSN, MSCN, FNP-C, on Emerging Therapies and Women’s Health Priorities in Multiple Sclerosis Katrina Bawden, MSN, MSCN, FNP-C

Published Date: 13 Feb 2026

A nurse practitioner at the Rocky Mountain MS Clinic discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women’s health.

Read Full News

Latest News

ISC 2026 Stroke Updates: Extended Time Windows and Secondary Prevention Strategies Ava L. Liberman, MD, Isabella Ciccone, MPH

Ava L. Liberman, MD, assistant professor of clinical neurology at Weill Cornell Medicine, shared key takeaways from stroke data presented at the 2026 International Stroke Conference.

Interpreting the DAWN Trial: Where Anti-CD38 Therapy May Fit in NMOSD Care Marco Meglio

Neurologists Michael Levy, MD, PhD, and Fu-Dong Shi, MD, PhD, discuss the rationale, design, and clinical implications of the phase 3 DAWN trial evaluating daratumumab in aquaporin-4–positive NMOSD.

CD-38 Monoclonal Antibody Daratumumab Shows Promise as Treatment for NMOSD in Phase 3 DAWN Study Marco Meglio

Phase 3 DAWN data show daratumumab cuts NMOSD relapse risk 76%, stays well tolerated, and may improve disability, signaling a new targeted option.

American College of Physicians Policy Paper Recommends Retiring 'Provider' Term for Physicians Isabella Ciccone, MPH

ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.

This Week on NeurologyLive® — February 9, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Ultragenyx Puts BLA for MPS IIIA Gene Therapy UX111 in Front of FDA Again Noah Stansfield

Ultragenyx seeks FDA accelerated approval for UX111 gene therapy in Sanfilippo syndrome, citing neurologic benefit and the use of cerebral spinal fluid heparan sulfate data.

Todays Updates

NeurologyLive® Brain Games: February 8, 2026 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on diagnosing parasomnias!

Remelyinating Drug Bazedoxifene Fails to Meet End Points in Phase 2 Study of Multiple Sclerosis Louie Pasculli

Late-breaking data from the 2026 ACTRIMS Forum showed that bazedoxifene acetate failed to improve remyelination outcomes in midlife women with relapsing MS, despite a favorable safety profile.

FDA Accepts New Drug Application for Orexin Agonist Oveporexton in Narcolepsy Type 1, Grants Priority Review Isabella Ciccone, MPH

The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.

Cutaneous Oncology Updates for 2026, With Paul Nghiem, MD, PhD Paul Nghiem, MD, PhD

Paul Nghiem highlights several key takeaways from his talk on cutaneous oncology, touching on various advances in skin cancer management.

VALIANT: Verekitug Reduces Average Annual Asthma Flare-Ups in Phase 2 Trial

VALIANT: Verekitug Reduces Average Annual Asthma Flare-Ups in Phase 2 Trial

REZOLVE-AD: Rezpegaldesleukin Improves Symptoms of Atopic Dermatitis

REZOLVE-AD: Rezpegaldesleukin Improves Symptoms of Atopic Dermatitis

Todays Updates

NeurologyLive® Brain Games: February 8, 2026 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on diagnosing parasomnias!

Remelyinating Drug Bazedoxifene Fails to Meet End Points in Phase 2 Study of Multiple Sclerosis Louie Pasculli

Late-breaking data from the 2026 ACTRIMS Forum showed that bazedoxifene acetate failed to improve remyelination outcomes in midlife women with relapsing MS, despite a favorable safety profile.

FDA Accepts New Drug Application for Orexin Agonist Oveporexton in Narcolepsy Type 1, Grants Priority Review Isabella Ciccone, MPH

The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.

Cutaneous Oncology Updates for 2026, With Paul Nghiem, MD, PhD Paul Nghiem, MD, PhD

Paul Nghiem highlights several key takeaways from his talk on cutaneous oncology, touching on various advances in skin cancer management.

VALIANT: Verekitug Reduces Average Annual Asthma Flare-Ups in Phase 2 Trial

VALIANT: Verekitug Reduces Average Annual Asthma Flare-Ups in Phase 2 Trial

REZOLVE-AD: Rezpegaldesleukin Improves Symptoms of Atopic Dermatitis

REZOLVE-AD: Rezpegaldesleukin Improves Symptoms of Atopic Dermatitis

Latest News

Ava L. Liberman, MD, assistant professor of clinical neurology at Weill Cornell Medicine, shared key takeaways from stroke data presented at the 2026 International Stroke Conference.

Neurologists Michael Levy, MD, PhD, and Fu-Dong Shi, MD, PhD, discuss the rationale, design, and clinical implications of the phase 3 DAWN trial evaluating daratumumab in aquaporin-4–positive NMOSD.

Phase 3 DAWN data show daratumumab cuts NMOSD relapse risk 76%, stays well tolerated, and may improve disability, signaling a new targeted option.

ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.

Here's some of what is coming soon to NeurologyLive® this week.

Ultragenyx seeks FDA accelerated approval for UX111 gene therapy in Sanfilippo syndrome, citing neurologic benefit and the use of cerebral spinal fluid heparan sulfate data.

News All Time

Cladribine Maintains Efficacy, Safety Profile in Older Patients With Multiple Sclerosis Marco Meglio

Real-world phase 4 data show cladribine keeps relapse rates low and safety steady in relapsing MS patients, including those 65+.

Subgroup Signals Emerge for rFVIIa in Acute Intracerebral Hemorrhage in Phase 3 FASTEST Trial Marco Meglio

FASTEST finds rFVIIa curbs ICH bleeding fast but adds clot risk; ultra-early and spot-sign patients show promise as Part 2 continues.

Late-Breaking CHOICE 2 Data Indicate Alteplase Displayed Improved Stroke Recovery Louie Pasculli

Adding intra-arterial alteplase after successful endovascular thrombectomy significantly improved 90-day functional outcomes in patients with large-vessel acute ischemic stroke, according to late-breaking data from the phase 3 CHOICE2 trial.

Cladribine Tablets Show Ability to Improve or Stabilize Cognitive Function in Patients With Relapsing Multiple Sclerosis Noah Stansfield

The analysis included 280 patients from CLARIFY-MS extension and 219 patients from MAGNIFY-MS extension, a total of 499 patients with at least 4 years of follow-up.

Real-World Data Analysis Highlight Clinical Profiles and Inebilizumab Use Patterns in NMOSD Isabella Ciccone, MPH

A cohort analysis, presented at ACTRIMS 2026, provided insight into the clinical characteristics, disease burden, and treatment sequencing of patients with neuromyelitis optica spectrum disorder treated with inebilizumab.

CREST-2 Substudy Shows No Cognitive Benefit of Carotid Revascularization in Asymptomatic Carotid Stenosis Isabella Ciccone, MPH

Late-breaking data from a substudy of the CREST-2 trial revealed that carotid revascularization did not show greater improvements in cognitive function compared with intensive medical management.

Biomarker Data Across Studies Support Disease-Targeted Effects of Valiltramiprosate Marco Meglio

Newly reported data showed that oral valiltramiprosate lowers p-tau217 and links to cognitive and brain-volume benefits in early Alzheimer disease.

NeuroVoices: Benjamin Tolchin, MD, FAAN, on First-Ever AAN Guidelines for Functional Seizures Marco Meglio

The director of the Center for Clinical Ethics at Yale New Haven Health discussed the rationale behind the newly published AAN guidelines on functional seizures, outlining diagnostic priorities, evidence-based treatment recommendations, and key gaps.

National Women Physicians Day: Perspectives From Riley Bove, MD Louie Pasculli, Riley Bove, MD

Riley Bove, MD, MS, associate professor of neurology at the University of California San Francisco, shares her personal view on National Women’s Physician’s and why it’s important for clinicians and patients in the field.

Women Physicians Day 2026: Prioritizing Whole-Person Care for Women With Movement Disorders Isabella Ciccone, MPH, Jill Farmer, DO, MPH, FCPP, DipABLM, Kelly Papesh, DNP, APRN, FNP-C, CMRD, Madhureeta Achari, MD, Joanna Dearlove, MD

As part of National Women Physicians Day, a group of women clinicians discussed various topics in the care for women with movement disorders.

National Women Physicians Day: Learning, Leading, and Lifting Others in Neurology Marco Meglio, Merit Cudkowicz, MD, MSc

ALS expert Merit Cudkowicz, MD, MSc, provided thoughts for National Women Physicians Day, reflecting on resilience in ALS research, the power of mentorship, and how leadership and advocacy can shape a meaningful career in neurology.

National Women Physicians Day: Women Driving Change in Neurology Louie Pasculli

In honor of National Women Physician’s Day, the NeurologyLive® team highlighted recent studies on women transforming neurologic care and advancing women’s health.

National Women Physicians Day: Insights From Aleksandra Pikula, MD, DipABPN, DipABLM, FELMO Aleksandra Pikula, MD, DipABPN, DipABLM, FELMO, Louie Pasculli

Aleksandra Pikula, MD, DipABPN, DipABLM, FELMO, director of the JS Sonshine Center, shares her personal view on National Women Physician’s and why it’s important for clinicians and patients in the field.

VMAT2 Inhibitor NBI-1065890 Heads to Phase 2 Study in Tardive Dyskinesia Marco Meglio

Neurocrine Biosciences launches a Phase 2 trial for NBI-1065890, targeting tardive dyskinesia with promising new treatment options.

National Women Physicians Day: Janis Miyasaki, Neuropalliative Care, and Advancing Women Leadersip Marco Meglio, Janis Miyasaki, MD, MEd, FRCPC, FAAN

Janis Miyasaki, MD, MEd, FRCPC, FAAN, a pioneer in neuropalliative care, provided clinical thoughts and perspectives on National Women Physicians Day and the ways to promote women leadership within the neurology field.

This Week on NeurologyLive® — February 2, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Recommended News For You

Dual-action mRNA vaccine takes aim at aggressive skin cancer

Many patients learn they could have cancer in the emergency department

Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC

Prostate cancer relapse after radiotherapy is strongly predicted by biological markers.

FDA Leaders Explain Their Choice Regarding Cancer Risk Warning in CAR-T Investigation.

What Could This Exploratory 5-Year Survival Data in Adjuvant NSCLC Treatment Mean?

Electronic Sepsis Alerts; Reducing Plaques in Coronary Arteries

Recommended Articles For You

Understanding Abemaciclib: A Breakthrough Treatment for Breast Cancer  

How AI, Multi-Omics, and Real-World Evidence are Redefining Oncology Research and Shaping Cancer Care? 

A New Hope: Exploring Treatment Options for Waldenstrom's Macroglobulinemia 

Unlocking the Potential of Lymphocytes: Exploring the Role of These Immune System Cells 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

CAR T-Cell Therapy in Functional High-Risk Multiple Myeloma

2.

Analysis of NRG trial in limited-stage small cell lung cancer suggests QOL benefit with twice- vs. once-daily radiation

3.

Mammo Responsibility Increases Screening; Opioids for Pain Related to Cancer? Ignored CRC Signs.

4.

A garden can save your life

5.

In MDS at Lower Risk, Novel Therapy Diminished Transfusion Dependency.

1.

Decoding the Failures in Acute Myeloid Leukemia Treatment: Mechanisms, Pathways, & Survival Outcomes

2.

Sound Waves and Self-Destruction: A Promising Nanotech Weapon in the Fight Against Cancer

3.

Mechanistic Depth and Clinical Impact of Rusfertide, Onyvide, IV Avastin, and Pemfexy

4.

Bridging Heart and Cancer Care: The Essential Framework of a Modern Cardio-Oncology Program

5.

Living with Shwachman-Diamond Syndrome: A Journey of Hope and Strength

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary

2.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

3.

"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC

4.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

5.

Optimizing Treatment Options in Advanced Urothelial Carcinoma

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot